Multimodal foundation models in action: Applications across drug development
Tempus, Daiichi Sankyo and AbbVie discuss the potential of novel multimodal AI, and its applications across drug development, from translational research to biomarker strategy and clinical deployment.
Session highlights
Join leaders from Tempus, Daiichi Sankyo, and Abbvie for a conversation on how specialized, multimodal foundation models are creating a single AI backbone that spans the entire drug development and commercialization lifecycle — from predicting treatment benefit and payload sensitivity, to gaining insights on patient biology across modalities, to predicting trial scenarios and closing testing gaps after approval. This session will cover:
How specialized, multimodal foundation models — trained on deep, longitudinal, real-world data — uncover insights general-purpose AI models can't
Novel, emerging applications of multimodal foundation models across the drug development lifecycle
What it takes to bring these tools from proof-of-concept to the clinic — validation, regulatory engagement, and choosing the right deployment partner
Webinar
Conference
